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SIJMMARY
Resistance to cisplatin (cDDP) is a major limitation to the clinical effectiveness of this
drug. Many in vifto studies have revealed that cDDP resistance has a multifactorial character,
involving decreased drug accumulation, increased drug detoxification potential, as well as
altered DNA repair capacity of resistant cells. In addition, other factors also have been
suggested to play a role in cDDP resistance, such as altered drug target accessibility as a result
of altered chromatin structure, altered intracellular signalling after drug exposure, altered
cellular processing of DNA damage and/or reduced susceptibility to induction of a specific form
of cell death such as apoptosis. Several approaches have been used to try to decrease the
problem of cDDP resistance. These comprise the development of new platinum analogues that
circumvent known resistance mechanisms, as well as the use of combination treatments, in
which cDDP is combined with other (pharmacological) agents, chosen on basis of their potential
to interfere with specific resistance mechanisms. However, until now the success of these
treatments has been limited, likely due to the fact that they only interact with one aspect of
cDDP resistance, leaving other components of resistance unaffected (chapter 1).
In the current study the potential of hyperthermia, a treatment of cells a few degrees
above their growth temperature, to interfere with cDDP resistance was explored. Hyperthermia
can not only lead to cell killing by itself, but it can also enhance the sensitivity of cells to
treatment with radiation and a variety of chemotherapeutic drugs, including cDDP. The effects
of hyperthermia on cellular metabolism are diverse, and include many aspects that might affect
cDDP sensitivity and resistance (chapter 1). The purpose of the experiments described in this
thesis was therefore to investigate the effectiveness of hyperthermia to reduce cDDP resistance.
This was done using murine cDDP sensitive (EN) and resistant (ER) Ehrlich Ascites Tumor
(EAT) cells, as well as in a human small cell lung carcinoma cell line (GLCr) and its cDOP
resistant subline (GLC'-cDDP).
228
Two different assays were used to quantify hyperthermia and cDDP-induced cellular
toxicity. The microculture tetrazolium assay (MTT assay), a rapid assay that records both loss
of clonogenicity and alterations in cellular growth rates, was compared to the soft agar
clonogenic survival assay, explicitly scoring the ability of cells to divide indefrnitely. The
results (chapter 3) show that, even though the data obtained with both assays were qualitatively
similar, the applicability of the MTT assay to measure thermochemosensitization is very limited
due to its inability to measure more than one log of cell killing. For this and other reasons, it
was concluded that the MTT assay is of little value for studying the interaction between
hyperthermia and cDDP, and that it also can not be used for predictive or treatment monitoring
purposes in a clinical setting of thermochemotherapy.
The effectiveness of single heat treatments applied simultaneously with cDDP to reduce
in viffo acquired cDDP resistance was investigated in chapters 2 and 3. Hyperthermia
treatments at 42" , 43"C and 44"C were found to be able to sensitize all cell lines to the
cytotoxic action of cDDP to a considerable xtent (ranging from 1.5 to almost 7-fold). In most
cases the level of cDDP sensitization was compa,rable in cDDP sensitive and resistant cells.
However, prolonged heat treatments at 43"C led to more extensive sensitization in the resistant
cells than in the cDDP sensitive cells, leading to a reduction in the resistance factor.
When thermochemotherapy is used clinically, the treatment protocol may consist of
multiple heat treatments. In this case development of thermotolerance, a transient state of heat
resistance that cells acquire when they have been exposed to prior heating, must be considered.
The state of thermotolerance per se was found not to affect the cDDP sensitivity at 37"C.
However, the sensitizing effect of a (second) heat treatment applied simultaneously with cDDP
was reduced in thermotolerant cells (chapter 4). So in the case of thermotolerance
development, not only the direct hyperthermic cell killing, but also hyperthermic cDDP
sensitization is reduced. Therefore, thermotolerance should be avoided in thermochemotherapy.
Although the ability of prolonged heating at 43'C to (partially) reverse acquired cDDP
resistance is rather promising, its applicability with the current clinical hyperthermia equipment
may be limited, as it seems to be difficult to heat tumors to such high temperatures for a
sufficient period of time. Therefore a step-down heating schedule (short pre-treatment at a high
temperature (>42'C), immediately before a treatment at a lower temperature (<42'C)) was
explored for its efficacy to enhance cDDP sensitivity (chapter 5). A short high temperature
(44'C) exposure enhanced the cytotoxicity of mild heat shock (41"C). However, the efficacy of
41"C to increase cDDP sensitivity was not enhanced by the pre-treatment at 44'C. The total
cDDP sensitizing effect of this treatment schedule was comparable to the additive effects of the
two heat treatments when given separately. So, unlike the situation for thermotolerance
(chapter 4) where reduced heat killing by a second heat treatment was paralleled by reduced
thermochemosensitization, an increase in heat killing by step-down heating did not lead to an
increase in the extent of thermochemosensitization. The observed effects of step-down heating
were comparable in sensitive and resistant cells. So, the step-down heating schedule, unlike the
43'C treatment, did not lead to a decrease of the cDDP resistance factor. Although this may
seem somewhat disappointing, the total cytotoxicity caused by this treatment protocol was very
large in all cell lines. The addition of a short pretreatment at 44"C led to l0-fold more cell
illine than )DDP with 4I'C alone. Ifris was due to (he extra hypcrthermic cel\ killing causcd
y the step-down heating and by the extra cDDP sensitizing etl'ect of the pre-treatment at 44'C.
o, despite the fact that cDDP resistance was not specifically affected, this treatment schedule
ould have a substantial impact on cDDP efficacy in the clinic even when cDDP resistance has
eveloped.
The mechanism of hyperthermic enhancement of cDDP sensitivity was found to be
rultifactorial (chapter 6). Heating cells at 43"C during cDDP exposure was found to increase
rug accumulation significantly in both cDDP-resistant cell lines, but had (almost) no effect on
Lrug accumulation in both cDDP-sensitive cell lines. Despite this, the formation of cDDP-DNA
dducts was significantly increased in all cell lines studied. A possible explanation for this could
re an effect of hyperthermia on glutathione levels (GSH). GSH is the main non-protein thiol in
he cell and plays an important role in the cellular detoxification machinery. Elevated GSH
evels are often found in cDDP resistant cells, including the ER and GLC.-cDDP cell lines used
rere. The results in chapter 2, however, clearly show that in both the EN and ER cell lines
rimost complete GSH depletion prior to cDDP (and heat) treatment did not lead to significant
ilterations in cDDP sensitivity at 37oC, nor at the hyperthermic temperatures. Therefore, at
east in these cells, overall GSH levels do not play a determining role in cDDP toxicity nor in
:he effects of heat on cDDP sensitivity. This indicates that heat effects on GSH levels cannot
:xplain why in some cases higher adduct levels are found at hyperthermic temperatures, despite
ilmost unaltered drug accumulation. In addition to the observed increased adduct formation
immediately after heat and cDDP exposure, a trend was apparent that ongoing formation of
gDDP-DNA adducts after the end of cDDP treatment was enhanced and/or adduct removal was
decreased in heated cells, resulting in relatively more DNA damage remaining at 24 hours after
the end of cDDP exposure. From these data (and correlation analysis thereof (chapters 6 and
E)) it was concluded that the mechanism by which heat sensitizes cells for cDDP action is the
sum of multiple factors, including heat effects on accumulation, adduct formation and adduct
processing. This is likely to be one of the reasons why hyperthermia has been found to be such
a potent enhancer of cDDP cytotoxicity, and in addition stresses its potential to affect oDDP
sensitivity in different cDDP resistant cells that display a variety of resistance mechanisms.
Cells synthesize a specific set of proteins (so-called heat shock proteins (HSPs)) when
they are exposed to stress-inducing agents such as hyperthermia, chemical agents and some
cytotoxic drugs. For heat shock, HSPs are closely associated with the development of
lhermotolerance. For cDDP sensitivity the role of HSP expression is obscure. In chapter 7 we
found that continuous cDDP incubation increased HSP27 protein levels in GLC. cells, but not
in the resistant subline. This was not a general stress response, since other (main) HSPs were
not elevated in either cell line. HSP27 mRNA levels were not significantly altered, indicating
lhat increased protein levels may be caused by altered protein stability. One of the factors that
;ould influence this is the phosphorylation status of the protein. Indeed cDDP exposure was
found to induce HSP27 phosphorylation.
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Recently it has been suggested that the expression of certain HSPs may be prognostic
markers in several tumor types. One of the putative explanations for this may be an involvement
of HSPs in determining cellular sensitivity to chemotherapeutic drugs, including oDDP. This
was evaluated in a panel of human tumor cell lines with a wide variety of intrinsic cDDP
sensitivities (chapter 7). In addition, two sets of human cell lines with in vlrro acquired cDDP
resistiance were studied. No correlation was found between the constitutive expression of the
main HSPs and cDDP sensitivity when all cell lines, irrespective of tissue of origin, were
considered. However, for the three cell lines derived from germ cell carcinomas HSP27
expression was inversely related to cDDP sensitivity; i.e. decreased HSP27 levels were
associated with decreased sensitivity. Also in both cell lines with in vitro acquired resistance
decreased HSP27 levels were found. Thus, although no general relationships between HSP
expression and cDDP sensitivity are apparent (in contrast to what has been suggested previously
in the literature), high HSP27 expression in vitro relates to high sensitivity to cDDP treatment
in some tumor types. This could relate to reported clinical data on high HSP27 levels in tumors
correlating with good prognosis.
Finally, the results presented in this thesis were compared to data re-analyzed, from the
literature to try to generate a more generalized concept regarding hyperthermic enhancement of
cDDP cytotoxicity (chapter 8). In accordance with our own dala, it seems that the
hyperthermic enhancement of cDDP sensitivity cannot solely be explained by altered drug
accumulation and cDDP-DNA adduct formation. DNA damage processing has to be included.
Moreover, it may be necessary to consider the spectrum of cDDP-DNA adducts that are
formed, as well as to consider the amount of adducts in specific sequences (e.9. active genes)
rather than in the genome overall, to fully comprehend the hyperthermic effects on cDDP
sensitivity and resistance.
In conclusion, although the mechanism of hyperthermic cDDP sensitization has not been
completely unraveled yet, the data in this thesis emphasize the promising potential of
hyperthermia to increase the clinical effectiveness of cDDP in cases where local control is a
problem, especially but not exclusively once resistance to cDDP has developed. This seems to
be true irrespective of which resislance mechanisms to oDDP have been acquired. Using
hyperthermia, the cDDP sensitivity of resistant cells can be restored to and even increased
beyond the level of cDDP sensitivity of the parenNal cells. In the clinic this implies that tumors
that have become refractory to cDDP treatment could be made responsive to cDDP again by
using combined heat and cDDP application. Therefore, hyperthermia treatments combined with
cDDP should be explored in well-designed clinical trials, in particular in patients that have
become refractory to cDDP treatment.
